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BACKGROUND: Tankyrase 1 (TNKS1) and Tankyrase 2 (TNKS2) are two proteins that form a distinct subgroup inside the PARP family. Both TNKS share 82% of
its sequence and have been linked to different cellular functions such as mitotic progression, glucose metabolism, stress granule formation and Wnt signaling.
Furthermore, altered levels of TNKS1 and/or TNKS2 expression have been reported in several types of cancer such as colon, lung or brain. Both tankyrases synthesize
linear chains of poly(ADP-ribose) (PAR) to produce posttranslational modifications of their target proteins and also itself through automodification. PARylation by
TNKS appears to be tightly linked to ubiquitination by ubiquitin E3 ligases like RNF146. Deficient angiogenesis leads to tumor hypoxia resulting in increased
aggressiveness and therapeutic resistance. The adaptation to this situation is carried out by the heterodimeric transcription factors hypoxia-inducible factor (HIF). In
particular, the oxygen-dependent protein HIF-1 /HIF-2 and the constitutively expressed protein HIF-1 are responsible for the induction of genes that allow the
adaptation and survival of cells to hypoxia.
AIM: Previous results from our group have shown that the posttranslational modification by PARylation is needed for the optimal activation of HIF-mediated
response to hypoxia, affecting both protein stability and transcriptional activation. In view of the pivotal role of TNKS-derived poly(ADP-ribose) synthesis in the
control of protein stability, we aimed to elucidate the implication of TNKS in the regulation of HIF-1 turnover and function in different tumor settings.
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FIG 1. (A) TNKS1/2 structure and functions. Both tankyrases have a similar structure which contains a conserved PARP
signature motif inside the C-terminus that catalyzes the synthesis and transfer of Poly-(ADP-ribose) to target proteins.
There is also an sterile alpha motif that is implicated in the formation of homo- and heterooligomers and five ankyrin
repeat clusters that allow protein-protein interactions. TNKS1 also present a His, Pro and Ser rich region at the N-
terminus which function is not well-known. (B) Protein degradation mechanism by TNKS1/2. Tankyrase 1/2 can add
chains of linear PAR to their substrates. Then, the ubiquitin E3 ligase RNF146 is able to recognize the linear PAR due to
its WWE domain and synthesize a Lys48-linked polyubiquitin chain that lead the protein to degradation via proteasome.
This mechanism is well-known, but there are other ubiquitin links involving Lys11, Lys27 or Lys63 that trigger other
biological responses like disruption of complexes, endosomal sorting or lysosomal degradation.
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FIG 4. Western blot analysis of HIF-1 expression after TNKS1/2 silencing with siRNA. (A) HEK-293T and (B) HeLa cells were
transfected with TNKS1 (60 nM) and/or TNKS2 (30 nM) siRNA during 48 hours, and incubated in normoxia or hypoxia 1% for 4 hours.
HIF-1 was measured by Western blot and protein levels decrease with the loss of TNKS1/2.
FIG 3. LOSS OF HIF-1 PROTEIN STABILITY AND RELATED-GENE GLUT1 mRNA 
AFTER TNKS1/2 INHIBITION WITH XAV939 IN HEK-293T AND MUM2B CELLS
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FIG 3. Western blot analysis of HIF-1 protein and related-gene Glut1 mRNA expression levels at different doses of TNKS1/2
inhibitor XAV939. (A) HEK-293T and (B) MUM 2B cells were treated with XAV939 during 24 hours (2.5 μM, 5 μM and 10 μM), and
incubated in normoxia or hypoxia 1% for 4 hours. PARP1 inhibitor Olaparib was used as a positive control. HIF-1 protein was
measured by Western blot and Glut1 mRNA gene expression was evaluated by qPCR and both levels decrease with XAV939 in a
dose dependent manner.
CONCLUSIONS: - Our experiments suggest that there is a connection between TNKS1/2 and HIF-1 , since TNKS inhibition or silencing TNKS1/2 results in
hh HIF-1 decreased stability and transcriptional activation.
- Immunoprecipitation results also hint at the formation of a complex between TNKS and HIF-1 , which is even stronger during normoxia.
- PARylation by tankyrases is implicated in HIF-1 stability and transcriptional activation capacity.
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FIG 5. Western blot analysis of HIF-1 protein with different TNKS1/2 inhibitors XAV939 and G007-LK during normoxia. HEK-
293T cells were treated with XAV939 10 μM (A) or G007-LK 5 μM (B) during 24 hours and incubated in normoxia with or without a
proteasome inhibitor MG132 3 μM for 4 hours. HIF-1 protein was measured by Western blot and protein levels decrease with
TNKS1/2 inhibition despite proteasome inhibition.
FIG 5. LOSS OF HIF-1 PROTEIN STABILITY AFTER TNKS1/2 INHIBITION WITH 
XAV939 AND G007-LK DURING NORMOXIA IN HEK-293T
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FUTURE REMARKS
- Generation and analysis of TNKS1, TNKS2 and TNKS1/2 CRISPR-
CAS9 models
- Test the effect of TNKS1/2 inhibition in colon cell lines
- Perform PARylation in vitro assays with wild type versus mutant
HIF-1
FIG 2. Interaction between HIF-1 AND TNKS1-2. HeLa cells were incubated in normoxia or hypoxia 1% for 4 hours. Proteins
were extracted and then (A) HIF-1 or (B) TNKS1/2 were immunoprecipitated with an specific antibody. Western blot analysis of
both proteins indicate the existence of an interaction. (C) Confocal microscopy analysis showing HIF-1 and TNKS1/2 localization.
HeLa cells were immune-stained with anti-TNKS1/2 and anti- HIF-1 and Alexa 488-conjugated anti-mouse IgG and Alexa 594-
conjugated anti-rabbit IgG respectively.
FIG 2. INTERACTION BETWEEN HIF-1 AND TNKS1/2 IN HELA CELLS
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